Stay updated on Durvalumab and Tremelimumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.

Latest updates to the Durvalumab and Tremelimumab in NSCLC Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.5.2 to v3.5.3, indicating a new version of the page's revision history. This reflects an update to the page's metadata without altering the underlying study data or functionality.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedRevision history updated: added v3.5.2 and removed v3.5.0.SummaryDifference0.1%

- Check26 days agoNo Change Detected
- Check48 days agoChange DetectedRevision history shows an addition of v3.5.0 and a deletion of v3.4.3. These entries document the version updates for the page.SummaryDifference0.1%

- Check55 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. No user-facing content or functionality changes are introduced.SummaryDifference0.1%

- Check62 days agoChange DetectedLatest history entry adds Contacts/Locations and Study Status to the study record. A deletion was recorded on 2025-09-16.SummaryDifference0.3%

- Check83 days agoChange DetectedAdded a new revision entry 'Revision: v3.4.2' to the version history. Removed the government funding lapse notice; these changes do not affect the study record content.SummaryDifference0.4%

Stay in the know with updates to Durvalumab and Tremelimumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab and Tremelimumab in NSCLC Clinical Trial page.